Empagliflozin (brand names: Jardiance, Synjardy) is an oral antihyperglycemic agent belonging to the SGLT-2 inhibitor class. It functions by inhibiting renal glucose reabsorption, lowering the renal glucose threshold, and promoting urinary glucose excretion. It is primarily indicated for the treatment of type 2 diabetes mellitus in adults.

AccuSift provides high-performance competitive antibody pairs for empagliflozin detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 1.1 ng/mL